{"filing":{"accession_number":"0001493152-26-030033","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226030033/form8-k.htm"},"events":[{"id":13718,"run_id":12186,"accession_number":"0001493152-26-030033","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses new preclinical pharmacology data on Mira-55, a lead cannabinoid analog in development for chronic inflammatory pain. The data demonstrates differentiated mechanism of action and anxiolytic activity relative to THC, supporting continued advancement toward IND submission. This is a material operational/clinical milestone for a clinical-stage pharmaceutical company, as it provides evidence supporting the therapeutic profile and development strategy of a key pipeline asset. The disclosure is made via Item 7.01 (Regulation FD Disclosure) with a press release exhibit, typical for material clinical or research updates that do not fit other specific 8-K categories.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":10938,"accession_number":"0001493152-26-030033","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses new preclinical pharmacology data on Mira-55, a lead cannabinoid analog in development for chronic inflammatory pain. The data demonstrates differentiated mechanism of action and anxiolytic activity relative to THC, supporting continued advancement toward IND submission. This is a material operational/clinical milestone for a clinical-stage pharmaceutical company, as it provides evidence supporting the therapeutic profile and development strategy of a key pipeline asset. The disclosure is made via Item 7.01 (Regulation FD Disclosure) with a press release exhibit, typical for material clinical or research updates that do not fit other specific 8-K categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:02:41.477628+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-25"}]}